PL3746114T3 - Kompozycje do zastosowania w leczeniu zaćmy - Google Patents
Kompozycje do zastosowania w leczeniu zaćmyInfo
- Publication number
- PL3746114T3 PL3746114T3 PL19702553.9T PL19702553T PL3746114T3 PL 3746114 T3 PL3746114 T3 PL 3746114T3 PL 19702553 T PL19702553 T PL 19702553T PL 3746114 T3 PL3746114 T3 PL 3746114T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- treat cataract
- cataract
- treat
- Prior art date
Links
- 208000002177 Cataract Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01171—Protein-fructosamine 3-kinase (2.7.1.171)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154064 | 2018-01-30 | ||
| PCT/EP2019/051961 WO2019149648A1 (en) | 2018-01-30 | 2019-01-28 | Compositions for use to treat cataract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3746114T3 true PL3746114T3 (pl) | 2023-01-16 |
Family
ID=61094279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19702553.9T PL3746114T3 (pl) | 2018-01-30 | 2019-01-28 | Kompozycje do zastosowania w leczeniu zaćmy |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11478499B2 (pl) |
| EP (1) | EP3746114B1 (pl) |
| JP (1) | JP7213891B2 (pl) |
| CA (1) | CA3088239A1 (pl) |
| ES (1) | ES2917628T3 (pl) |
| PL (1) | PL3746114T3 (pl) |
| WO (1) | WO2019149648A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12171811B2 (en) | 2018-09-14 | 2024-12-24 | Universiteit Gent | Compositions for use to treat advanced glycation end products-dependent ocular diseases |
| EP4245371A4 (en) * | 2020-11-17 | 2024-11-13 | Nagase Viita Co., Ltd. | Crystalline lens hardness adjustment agent |
| CA3210369A1 (en) * | 2021-03-08 | 2022-09-15 | Universiteit Gent | Treatment of eye diseases with fructosyl-amino acid oxidase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222533A1 (en) * | 2002-04-29 | 2003-11-17 | Protemix Corporation Limited | Proteins with deglycating activities and methods of using same |
| EP2152231A1 (en) * | 2007-06-11 | 2010-02-17 | Chanel Parfums Beauté | Use of active agents for stimulating the expression of fn3k and/or fn3k rp for combating ageing of the skin |
| CA2853379C (en) * | 2011-10-27 | 2020-11-24 | Wellstat Ophthalmics Corporation | Vectors encoding rod-derived cone viability factor |
| US20180325854A1 (en) | 2015-11-06 | 2018-11-15 | Accuitis Pharmaceuticals, Inc. | Use of proteasome inhibitors to treat ocular disorders |
-
2019
- 2019-01-28 JP JP2020562841A patent/JP7213891B2/ja active Active
- 2019-01-28 WO PCT/EP2019/051961 patent/WO2019149648A1/en not_active Ceased
- 2019-01-28 ES ES19702553T patent/ES2917628T3/es active Active
- 2019-01-28 EP EP19702553.9A patent/EP3746114B1/en active Active
- 2019-01-28 PL PL19702553.9T patent/PL3746114T3/pl unknown
- 2019-01-28 CA CA3088239A patent/CA3088239A1/en active Pending
- 2019-01-28 US US16/964,149 patent/US11478499B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7213891B2 (ja) | 2023-01-27 |
| US20210030780A1 (en) | 2021-02-04 |
| CA3088239A1 (en) | 2019-08-08 |
| ES2917628T3 (es) | 2022-07-11 |
| WO2019149648A1 (en) | 2019-08-08 |
| JP2021515803A (ja) | 2021-06-24 |
| EP3746114A1 (en) | 2020-12-09 |
| US11478499B2 (en) | 2022-10-25 |
| EP3746114B1 (en) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202105907QA (en) | Compositions for drg-specific reduction of transgene expression | |
| ZA201803530B (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| ZA201801881B (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| GB201715639D0 (en) | Compositions for wound treatment | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| IL258032A (en) | Compounds and preparations for the treatment of ocular disorders | |
| IL249938B (en) | Preparations of antiviral substances for preventive treatment | |
| IL261774B (en) | Preparations for the treatment of skin problems | |
| PT3573620T (pt) | Composições para o tratamento da hipertensão | |
| EP3160460A4 (en) | Ketobutyrate compounds and compositions for treating age-related symptoms and diseases | |
| IL249640A0 (en) | Preparations for the treatment of nosebleeds | |
| PL3493823T3 (pl) | Składnik na bazie postbiotyki do leczenia zapalenia oka | |
| SG11202008959RA (en) | Composition for improving skin conditions | |
| GB201707462D0 (en) | Ocular compositions | |
| SG11202006144XA (en) | Composition for protecting cornea | |
| PL3746114T3 (pl) | Kompozycje do zastosowania w leczeniu zaćmy | |
| SMT202300229T1 (it) | Composizioni per trattare condizioni oftalmiche | |
| IL252543A0 (en) | Compounds for the treatment of degenerative retinal tissues | |
| PL3849596T3 (pl) | Kompozycje do zastosowania w leczeniu chorób oczu zależnych od końcowych produktów zaawansowanej glikacji | |
| IL263336B (en) | Compounds for the treatment of symphysiolysis | |
| GB201813783D0 (en) | Therapeutic compositions | |
| GB201811726D0 (en) | Therapeutic compositions |